
NYSE:RVTY
This summary was created by AI, based on 1 opinions in the last 12 months.
Revvity, a life sciences company, has recently shown promising performance after a prolonged period of stagnation. In October, the company reported solid financial results, leading to an increased full-year earnings forecast. This positive development suggests a turnaround in its fortunes and could indicate a bright future ahead for the company. Notably, Revvity is trading at a price-to-earnings (PE) ratio of 21, which is currently the lowest in its sector. This valuation may position it as an attractive investment opportunity for those looking for growth in the life sciences field.
Revvity is a American stock, trading under the symbol RVTY (previously RVTY-N on Stockchase) on the New York Stock Exchange (RVTY). It is usually referred to as NYSE:RVTY or RVTY
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on RVTY (previously RVTY-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Revvity.
Revvity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Revvity.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Revvity.
Revvity is covered by Stockchase experts and is worth watching.
On 2026-08-13, Revvity (RVTY) stock closed at a price of $117.50.
A life sciences company. After years of going nowhere, they finally posted good numbers last October and raised their full-year earnings forecast. Trades at 21x PE, the cheapest in the sector.